Our study shows that both serum levels of IL-23 and IL-17 are significantly increased in HT patients with newly diagnosed HT hypothyroid patients, euthyroid HT patients, and HT treated with levothyroxine patients respectively compared to the healthy control group. This evidence concerns the gene IL17A and hematocrit.